BIOMAT Database Logo BIOMAT Database Logo

Actinomycin D--the drug of choice for initial therapy of gestational trophoblastic disease. 1971

P J Winig, and D P Goldstein, and R L Shirley

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P J Winig, and D P Goldstein, and R L Shirley
Actinomycin D as the primary agent for gestational trophoblastic disease.
September 1975, Cancer,
P J Winig, and D P Goldstein, and R L Shirley
Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
January 2012, The Journal of reproductive medicine,
P J Winig, and D P Goldstein, and R L Shirley
Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies.
April 1974, Obstetrics and gynecology,
P J Winig, and D P Goldstein, and R L Shirley
Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, actinomycin-D, etoposide, cisplatin (EMA/EP).
January 2004, Archives of gynecology and obstetrics,
P J Winig, and D P Goldstein, and R L Shirley
Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy.
June 1985, Obstetrics and gynecology,
P J Winig, and D P Goldstein, and R L Shirley
[Metastatic trophoblastic disease treated with actinomycin D].
January 1975, Revista chilena de obstetricia y ginecologia,
P J Winig, and D P Goldstein, and R L Shirley
Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
November 1992, Obstetrics and gynecology,
P J Winig, and D P Goldstein, and R L Shirley
The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.
January 1997, Gynecologic oncology,
P J Winig, and D P Goldstein, and R L Shirley
Surgical therapy for gestational trophoblastic disease.
March 1994, The Journal of reproductive medicine,
P J Winig, and D P Goldstein, and R L Shirley
Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease.
January 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
Copied contents to your clipboard!